Jeronselvain CEO Deokgyu Kim Wins "2025 Global New Korean Award" in Medical Sector

From the left, Sangdeok Kim, Chairman of the International Korean Economic Cooperation Association, and Deokgyu Kim, CEO of Jeronselvain. Jeronselvain

Deokgyu Kim, CEO of Jeronselvain, a company specializing in the production of prescription drugs, announced on August 20 that he had received the "2025 Global New Korean Award" in the medical sector at the "2025 Outstanding National Assembly Members, Local Government Awards, and Global New Korean Awards" ceremony.

This award was organized by the "2025 Outstanding National Assembly Members and Local Government Legislative Awards & Global New Korean Awards" selection committee. The committee selects individuals who have demonstrated dedication to national and social development, a strong sense of patriotism, and have contributed to the advancement of their field based on professional expertise in a rapidly changing global environment. Deokgyu Kim was recognized as an awardee for his achievements in the field of biotechnology.

Kim was credited with developing "Prism Technology (Prism-T)," the world's first patented technology for uniform low-molecular-weight polynucleotide (PDRN) production. This technology enables the manufacture of nucleic acid fragments of consistent size and is regarded as a key achievement for its applications in regenerative medicine, dermatology, dentistry, and various other medical fields.

In particular, along with the "2025 Global New Korean Award," Kim also received a commendation from Assemblyman Kang Min-guk of the National Assembly's Political Affairs Committee, further acknowledging his contributions to the advancement of the medical and bio industries.

Deokgyu Kim, CEO of Jeronselvain, stated, "Jeronselvain is producing PDRN with unrivaled technology and is emerging as a leading global biotechnology company. We will continue to pursue professional development through close collaboration with domestic and international researchers and medical professionals, and expand our sales network in global markets such as North America, Europe, and Asia."

He added, "I am delighted that our research achievements have been officially recognized as contributing to the development of the medical and bio industries through this award. We will continue to devote ourselves to research and development for the improvement of public health and the advancement of the global healthcare industry."

This content was produced with the assistance of AI translation services.